Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,18948689,t(max),"The median t(max) changed from 4 to 3 h, although the change was not significant.",Prokinetics influence the pharmacokinetics of rabeprazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18948689/),h,4 to,4022,DB01129,Rabeprazole
,18948689,t(max),"The median t(max) changed from 4 to 3 h, although the change was not significant.",Prokinetics influence the pharmacokinetics of rabeprazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18948689/),h,3,4023,DB01129,Rabeprazole
,20533763,AUC(0-t),"The main pharmacokinetic parameters obtained were: AUC(0-t) 1415.88 +/- 505.46 and 1457.44 +/- 524.40 ng x h/ml, AUC(0-infinity) 1439.10 +/- 507.47 and 1479.81 +/- 527.83 ng h/ml, C(max) 678.24 +/- 278.93 and 657.83 +/- 250.86 ng/ml, t1/2 1.48 +/- 0.19 and 1.38 +/- 0.24 h, t(max) 3.8 +/- 0.8 and 3.7 +/- 0.5 h for the test and reference formulations, respectively.",Liquid chromatography-tandem mass/mass spectrometry method for the quantification of rabeprazole in human plasma and application to a pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20533763/),[h·ng] / [ml],1415.88,8696,DB01129,Rabeprazole
,20533763,AUC(0-t),"The main pharmacokinetic parameters obtained were: AUC(0-t) 1415.88 +/- 505.46 and 1457.44 +/- 524.40 ng x h/ml, AUC(0-infinity) 1439.10 +/- 507.47 and 1479.81 +/- 527.83 ng h/ml, C(max) 678.24 +/- 278.93 and 657.83 +/- 250.86 ng/ml, t1/2 1.48 +/- 0.19 and 1.38 +/- 0.24 h, t(max) 3.8 +/- 0.8 and 3.7 +/- 0.5 h for the test and reference formulations, respectively.",Liquid chromatography-tandem mass/mass spectrometry method for the quantification of rabeprazole in human plasma and application to a pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20533763/),[h·ng] / [ml],1457.44,8697,DB01129,Rabeprazole
,20533763,AUC(0-infinity),"The main pharmacokinetic parameters obtained were: AUC(0-t) 1415.88 +/- 505.46 and 1457.44 +/- 524.40 ng x h/ml, AUC(0-infinity) 1439.10 +/- 507.47 and 1479.81 +/- 527.83 ng h/ml, C(max) 678.24 +/- 278.93 and 657.83 +/- 250.86 ng/ml, t1/2 1.48 +/- 0.19 and 1.38 +/- 0.24 h, t(max) 3.8 +/- 0.8 and 3.7 +/- 0.5 h for the test and reference formulations, respectively.",Liquid chromatography-tandem mass/mass spectrometry method for the quantification of rabeprazole in human plasma and application to a pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20533763/),[h·ng] / [ml],1439.10,8698,DB01129,Rabeprazole
,20533763,AUC(0-infinity),"The main pharmacokinetic parameters obtained were: AUC(0-t) 1415.88 +/- 505.46 and 1457.44 +/- 524.40 ng x h/ml, AUC(0-infinity) 1439.10 +/- 507.47 and 1479.81 +/- 527.83 ng h/ml, C(max) 678.24 +/- 278.93 and 657.83 +/- 250.86 ng/ml, t1/2 1.48 +/- 0.19 and 1.38 +/- 0.24 h, t(max) 3.8 +/- 0.8 and 3.7 +/- 0.5 h for the test and reference formulations, respectively.",Liquid chromatography-tandem mass/mass spectrometry method for the quantification of rabeprazole in human plasma and application to a pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20533763/),[h·ng] / [ml],1479.81,8699,DB01129,Rabeprazole
,20533763,C(max),"The main pharmacokinetic parameters obtained were: AUC(0-t) 1415.88 +/- 505.46 and 1457.44 +/- 524.40 ng x h/ml, AUC(0-infinity) 1439.10 +/- 507.47 and 1479.81 +/- 527.83 ng h/ml, C(max) 678.24 +/- 278.93 and 657.83 +/- 250.86 ng/ml, t1/2 1.48 +/- 0.19 and 1.38 +/- 0.24 h, t(max) 3.8 +/- 0.8 and 3.7 +/- 0.5 h for the test and reference formulations, respectively.",Liquid chromatography-tandem mass/mass spectrometry method for the quantification of rabeprazole in human plasma and application to a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20533763/),[ng] / [ml],678.24,8700,DB01129,Rabeprazole
,20533763,C(max),"The main pharmacokinetic parameters obtained were: AUC(0-t) 1415.88 +/- 505.46 and 1457.44 +/- 524.40 ng x h/ml, AUC(0-infinity) 1439.10 +/- 507.47 and 1479.81 +/- 527.83 ng h/ml, C(max) 678.24 +/- 278.93 and 657.83 +/- 250.86 ng/ml, t1/2 1.48 +/- 0.19 and 1.38 +/- 0.24 h, t(max) 3.8 +/- 0.8 and 3.7 +/- 0.5 h for the test and reference formulations, respectively.",Liquid chromatography-tandem mass/mass spectrometry method for the quantification of rabeprazole in human plasma and application to a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20533763/),[ng] / [ml],657.83,8701,DB01129,Rabeprazole
,20533763,t1/2,"The main pharmacokinetic parameters obtained were: AUC(0-t) 1415.88 +/- 505.46 and 1457.44 +/- 524.40 ng x h/ml, AUC(0-infinity) 1439.10 +/- 507.47 and 1479.81 +/- 527.83 ng h/ml, C(max) 678.24 +/- 278.93 and 657.83 +/- 250.86 ng/ml, t1/2 1.48 +/- 0.19 and 1.38 +/- 0.24 h, t(max) 3.8 +/- 0.8 and 3.7 +/- 0.5 h for the test and reference formulations, respectively.",Liquid chromatography-tandem mass/mass spectrometry method for the quantification of rabeprazole in human plasma and application to a pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20533763/),h,1.48,8702,DB01129,Rabeprazole
,20533763,t1/2,"The main pharmacokinetic parameters obtained were: AUC(0-t) 1415.88 +/- 505.46 and 1457.44 +/- 524.40 ng x h/ml, AUC(0-infinity) 1439.10 +/- 507.47 and 1479.81 +/- 527.83 ng h/ml, C(max) 678.24 +/- 278.93 and 657.83 +/- 250.86 ng/ml, t1/2 1.48 +/- 0.19 and 1.38 +/- 0.24 h, t(max) 3.8 +/- 0.8 and 3.7 +/- 0.5 h for the test and reference formulations, respectively.",Liquid chromatography-tandem mass/mass spectrometry method for the quantification of rabeprazole in human plasma and application to a pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20533763/),h,1.38,8703,DB01129,Rabeprazole
,20533763,t(max),"The main pharmacokinetic parameters obtained were: AUC(0-t) 1415.88 +/- 505.46 and 1457.44 +/- 524.40 ng x h/ml, AUC(0-infinity) 1439.10 +/- 507.47 and 1479.81 +/- 527.83 ng h/ml, C(max) 678.24 +/- 278.93 and 657.83 +/- 250.86 ng/ml, t1/2 1.48 +/- 0.19 and 1.38 +/- 0.24 h, t(max) 3.8 +/- 0.8 and 3.7 +/- 0.5 h for the test and reference formulations, respectively.",Liquid chromatography-tandem mass/mass spectrometry method for the quantification of rabeprazole in human plasma and application to a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20533763/),h,3.8,8704,DB01129,Rabeprazole
,20533763,t(max),"The main pharmacokinetic parameters obtained were: AUC(0-t) 1415.88 +/- 505.46 and 1457.44 +/- 524.40 ng x h/ml, AUC(0-infinity) 1439.10 +/- 507.47 and 1479.81 +/- 527.83 ng h/ml, C(max) 678.24 +/- 278.93 and 657.83 +/- 250.86 ng/ml, t1/2 1.48 +/- 0.19 and 1.38 +/- 0.24 h, t(max) 3.8 +/- 0.8 and 3.7 +/- 0.5 h for the test and reference formulations, respectively.",Liquid chromatography-tandem mass/mass spectrometry method for the quantification of rabeprazole in human plasma and application to a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20533763/),h,3.7,8705,DB01129,Rabeprazole
,18223462,Cmax,"The mean dose-unadjusted and -adjusted Cmax of MPA with 30 mg lansoprazole were significantly lower than those without PPI (11.8 vs. 17.8 microg/mL, P = 0.0197, and 22.6 vs. 33.1 ng/mL/mg MMF, P = 0.0222, respectively).",Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223462/),[μg] / [ml],11.8,9335,DB01129,Rabeprazole
,18223462,Cmax,"The mean dose-unadjusted and -adjusted Cmax of MPA with 30 mg lansoprazole were significantly lower than those without PPI (11.8 vs. 17.8 microg/mL, P = 0.0197, and 22.6 vs. 33.1 ng/mL/mg MMF, P = 0.0222, respectively).",Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223462/),[μg] / [ml],17.8,9336,DB01129,Rabeprazole
,18223462,Cmax,"The mean dose-unadjusted and -adjusted Cmax of MPA with 30 mg lansoprazole were significantly lower than those without PPI (11.8 vs. 17.8 microg/mL, P = 0.0197, and 22.6 vs. 33.1 ng/mL/mg MMF, P = 0.0222, respectively).",Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223462/),[ng] / [mg·ml],22.6,9337,DB01129,Rabeprazole
,18223462,Cmax,"The mean dose-unadjusted and -adjusted Cmax of MPA with 30 mg lansoprazole were significantly lower than those without PPI (11.8 vs. 17.8 microg/mL, P = 0.0197, and 22.6 vs. 33.1 ng/mL/mg MMF, P = 0.0222, respectively).",Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223462/),[ng] / [mg·ml],33.1,9338,DB01129,Rabeprazole
,16087412,total time,"The peak was detected with an ultraviolet detector set at a wavelength of 288 nm, and the total time for chromatographic separation was approximately 25 min.","Determination of rabeprazole and its active metabolite, rabeprazole thioether in human plasma by column-switching high-performance liquid chromatography and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16087412/),min,25,21593,DB01129,Rabeprazole
,16087412,absolute recoveries,"Mean absolute recoveries were 78.0 and 88.3% for rabeprazole and rabeprazole thioether, respectively.","Determination of rabeprazole and its active metabolite, rabeprazole thioether in human plasma by column-switching high-performance liquid chromatography and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16087412/),%,78.0,21594,DB01129,Rabeprazole
,16087412,absolute recoveries,"Mean absolute recoveries were 78.0 and 88.3% for rabeprazole and rabeprazole thioether, respectively.","Determination of rabeprazole and its active metabolite, rabeprazole thioether in human plasma by column-switching high-performance liquid chromatography and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16087412/),%,88.3,21595,DB01129,Rabeprazole
,16087412,limits of,The limits of quantification were 1 ng/ml for rabeprazole and 3 ng/ml for rabeprazole thioether.,"Determination of rabeprazole and its active metabolite, rabeprazole thioether in human plasma by column-switching high-performance liquid chromatography and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16087412/),[ng] / [ml],1,21596,DB01129,Rabeprazole
,16087412,limits of,The limits of quantification were 1 ng/ml for rabeprazole and 3 ng/ml for rabeprazole thioether.,"Determination of rabeprazole and its active metabolite, rabeprazole thioether in human plasma by column-switching high-performance liquid chromatography and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16087412/),[ng] / [ml],3,21597,DB01129,Rabeprazole
,21110014,area under the plasma concentration-time curve (AUC(0-τ)),"After receiving a single and repeated doses of RPZ, the area under the plasma concentration-time curve (AUC(0-τ)) was 51.9 ± 22.1, 96.7 ± 27.6, and 188.4 ± 65.8 mg·min/L on day 1 and 59.3 ± 23.9, 106.7 ± 27.8, and 200.3 ± 79.0 mg·min/L on day 5 for the low-, middle-, and high-dose groups, respectively.",Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21110014/),[mg·min] / [l],51.9,24991,DB01129,Rabeprazole
,21110014,area under the plasma concentration-time curve (AUC(0-τ)),"After receiving a single and repeated doses of RPZ, the area under the plasma concentration-time curve (AUC(0-τ)) was 51.9 ± 22.1, 96.7 ± 27.6, and 188.4 ± 65.8 mg·min/L on day 1 and 59.3 ± 23.9, 106.7 ± 27.8, and 200.3 ± 79.0 mg·min/L on day 5 for the low-, middle-, and high-dose groups, respectively.",Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21110014/),[mg·min] / [l],96.7,24992,DB01129,Rabeprazole
,21110014,area under the plasma concentration-time curve (AUC(0-τ)),"After receiving a single and repeated doses of RPZ, the area under the plasma concentration-time curve (AUC(0-τ)) was 51.9 ± 22.1, 96.7 ± 27.6, and 188.4 ± 65.8 mg·min/L on day 1 and 59.3 ± 23.9, 106.7 ± 27.8, and 200.3 ± 79.0 mg·min/L on day 5 for the low-, middle-, and high-dose groups, respectively.",Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21110014/),[mg·min] / [l],188.4,24993,DB01129,Rabeprazole
,21110014,area under the plasma concentration-time curve (AUC(0-τ)),"After receiving a single and repeated doses of RPZ, the area under the plasma concentration-time curve (AUC(0-τ)) was 51.9 ± 22.1, 96.7 ± 27.6, and 188.4 ± 65.8 mg·min/L on day 1 and 59.3 ± 23.9, 106.7 ± 27.8, and 200.3 ± 79.0 mg·min/L on day 5 for the low-, middle-, and high-dose groups, respectively.",Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21110014/),[mg·min] / [l],59.3,24994,DB01129,Rabeprazole
,21110014,area under the plasma concentration-time curve (AUC(0-τ)),"After receiving a single and repeated doses of RPZ, the area under the plasma concentration-time curve (AUC(0-τ)) was 51.9 ± 22.1, 96.7 ± 27.6, and 188.4 ± 65.8 mg·min/L on day 1 and 59.3 ± 23.9, 106.7 ± 27.8, and 200.3 ± 79.0 mg·min/L on day 5 for the low-, middle-, and high-dose groups, respectively.",Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21110014/),[mg·min] / [l],106.7,24995,DB01129,Rabeprazole
,21110014,area under the plasma concentration-time curve (AUC(0-τ)),"After receiving a single and repeated doses of RPZ, the area under the plasma concentration-time curve (AUC(0-τ)) was 51.9 ± 22.1, 96.7 ± 27.6, and 188.4 ± 65.8 mg·min/L on day 1 and 59.3 ± 23.9, 106.7 ± 27.8, and 200.3 ± 79.0 mg·min/L on day 5 for the low-, middle-, and high-dose groups, respectively.",Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21110014/),[mg·min] / [l],200.3,24996,DB01129,Rabeprazole
,21110014,peak concentrations (C(max)),"The corresponding peak concentrations (C(max)) were 0.64 ± 0.11, 1.30 ± 0.26, and 2.6 ± 0.54 μg/mL on day 1 and 0.76 ± 0.15, 1.39 ± 0.25, and 2.91 ± 0.53 μg/mL on day 5, respectively.",Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21110014/),[μg] / [ml],0.64,24997,DB01129,Rabeprazole
,21110014,peak concentrations (C(max)),"The corresponding peak concentrations (C(max)) were 0.64 ± 0.11, 1.30 ± 0.26, and 2.6 ± 0.54 μg/mL on day 1 and 0.76 ± 0.15, 1.39 ± 0.25, and 2.91 ± 0.53 μg/mL on day 5, respectively.",Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21110014/),[μg] / [ml],1.30,24998,DB01129,Rabeprazole
,21110014,peak concentrations (C(max)),"The corresponding peak concentrations (C(max)) were 0.64 ± 0.11, 1.30 ± 0.26, and 2.6 ± 0.54 μg/mL on day 1 and 0.76 ± 0.15, 1.39 ± 0.25, and 2.91 ± 0.53 μg/mL on day 5, respectively.",Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21110014/),[μg] / [ml],2.6,24999,DB01129,Rabeprazole
,21110014,peak concentrations (C(max)),"The corresponding peak concentrations (C(max)) were 0.64 ± 0.11, 1.30 ± 0.26, and 2.6 ± 0.54 μg/mL on day 1 and 0.76 ± 0.15, 1.39 ± 0.25, and 2.91 ± 0.53 μg/mL on day 5, respectively.",Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21110014/),[μg] / [ml],0.76,25000,DB01129,Rabeprazole
,21110014,peak concentrations (C(max)),"The corresponding peak concentrations (C(max)) were 0.64 ± 0.11, 1.30 ± 0.26, and 2.6 ± 0.54 μg/mL on day 1 and 0.76 ± 0.15, 1.39 ± 0.25, and 2.91 ± 0.53 μg/mL on day 5, respectively.",Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21110014/),[μg] / [ml],1.39,25001,DB01129,Rabeprazole
,21110014,peak concentrations (C(max)),"The corresponding peak concentrations (C(max)) were 0.64 ± 0.11, 1.30 ± 0.26, and 2.6 ± 0.54 μg/mL on day 1 and 0.76 ± 0.15, 1.39 ± 0.25, and 2.91 ± 0.53 μg/mL on day 5, respectively.",Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21110014/),[μg] / [ml],2.91,25002,DB01129,Rabeprazole
,21110014,"AUC((0, τ))","The mean AUC((0, τ)) and C(max) ratios of repeated dose to single dose were 1.14, 1.10, and 1.06 on day 1 and 1.19, 1.07, and 1.12 on day 5 for the low-, middle-, and high-dose groups, respectively.",Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21110014/),,1.14,25003,DB01129,Rabeprazole
,21110014,"AUC((0, τ))","The mean AUC((0, τ)) and C(max) ratios of repeated dose to single dose were 1.14, 1.10, and 1.06 on day 1 and 1.19, 1.07, and 1.12 on day 5 for the low-, middle-, and high-dose groups, respectively.",Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21110014/),,1.10,25004,DB01129,Rabeprazole
,21110014,"AUC((0, τ))","The mean AUC((0, τ)) and C(max) ratios of repeated dose to single dose were 1.14, 1.10, and 1.06 on day 1 and 1.19, 1.07, and 1.12 on day 5 for the low-, middle-, and high-dose groups, respectively.",Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21110014/),,1.19,25005,DB01129,Rabeprazole
,21110014,"AUC((0, τ))","The mean AUC((0, τ)) and C(max) ratios of repeated dose to single dose were 1.14, 1.10, and 1.06 on day 1 and 1.19, 1.07, and 1.12 on day 5 for the low-, middle-, and high-dose groups, respectively.",Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21110014/),,1,25006,DB01129,Rabeprazole
,21110014,C(max),"The mean AUC((0, τ)) and C(max) ratios of repeated dose to single dose were 1.14, 1.10, and 1.06 on day 1 and 1.19, 1.07, and 1.12 on day 5 for the low-, middle-, and high-dose groups, respectively.",Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21110014/),,1.10,25007,DB01129,Rabeprazole
,21110014,C(max),"The mean AUC((0, τ)) and C(max) ratios of repeated dose to single dose were 1.14, 1.10, and 1.06 on day 1 and 1.19, 1.07, and 1.12 on day 5 for the low-, middle-, and high-dose groups, respectively.",Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21110014/),,1,25008,DB01129,Rabeprazole
,21110014,C(max),"The mean AUC((0, τ)) and C(max) ratios of repeated dose to single dose were 1.14, 1.10, and 1.06 on day 1 and 1.19, 1.07, and 1.12 on day 5 for the low-, middle-, and high-dose groups, respectively.",Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21110014/),,1.19,25009,DB01129,Rabeprazole
,24010577,Absolute bioavailability,"Absolute bioavailability of cobimetinib was 46.2% (24.2, CV %), likely due to metabolism rather than incomplete absorption.","Absolute bioavailability and effect of formulation change, food, or elevated pH with rabeprazole on cobimetinib absorption in healthy subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010577/),%,46.2,29126,DB01129,Rabeprazole
,24010577,systemic clearance,"The mean systemic clearance of cobimetinib was low (11.7 L/h [28.2, CV %]).","Absolute bioavailability and effect of formulation change, food, or elevated pH with rabeprazole on cobimetinib absorption in healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24010577/),[l] / [h],11.7,29127,DB01129,Rabeprazole
,16487225,relative AUC ratios,"The area under the plasma concentration-time curves (AUC) of (R)-rabeprazole in homEMs, hetEMs and PMs were 1.8-, 2.2- and 2.4-fold, respectively, greater than those of (S)-rabeprazole; the relative AUC ratios of (R)- and (S)-rabeprazole in homEMs, hetEMs and PMs were 1:1.1:2.1 and 1:0.9:1.5, respectively.",Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487225/),,1,30554,DB01129,Rabeprazole
,16487225,elimination half-life,"There was no difference between homEMs and PMs in the elimination half-life of (S)-rabeprazole, whereas the elimination half-life of (R)-rabeprazole was significantly longer in PMs than in homEMs [1.7 h (1.4, 2.0) (mean (95% confidence interval)]vs. 0.8 h (0.6, 1.0), respectively, P<0.0001).",Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487225/),h,1.7,30555,DB01129,Rabeprazole
,16487225,elimination half-life,"There was no difference between homEMs and PMs in the elimination half-life of (S)-rabeprazole, whereas the elimination half-life of (R)-rabeprazole was significantly longer in PMs than in homEMs [1.7 h (1.4, 2.0) (mean (95% confidence interval)]vs. 0.8 h (0.6, 1.0), respectively, P<0.0001).",Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487225/),h,0.8,30556,DB01129,Rabeprazole
,18806963,Extraction recoveries,Extraction recoveries were 72.3% for the drug and 79.1% for the internal standard.,High performance liquid chromatographic analysis of rabeprazole in human plasma and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806963/),%,72.3,32215,DB01129,Rabeprazole
,18806963,Extraction recoveries,Extraction recoveries were 72.3% for the drug and 79.1% for the internal standard.,High performance liquid chromatographic analysis of rabeprazole in human plasma and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806963/),%,79.1,32216,DB01129,Rabeprazole
,12820812,area under the concentration-time curve,"The mean +/- SD values of area under the concentration-time curve of rabeprazole and rabeprazole thioether were significantly higher in poor metabolizers than in extensive metabolizers on day 1 (5357 +/- 883 vs 1131 +/- 512 ng x hr/ml and 1703 +/- 432 vs 561 +/- 358 ng x hr/ml, respectively; p<0.001) and on day 4 (5601 +/- 669 vs 1619 +/- 778 ng x hr/ml and 1914 +/- 378 vs 511 +/- 360 ng x hr/ml, respectively; p<0.001).",Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12820812/),[h·ng] / [ml],5357,37004,DB01129,Rabeprazole
,12820812,area under the concentration-time curve,"The mean +/- SD values of area under the concentration-time curve of rabeprazole and rabeprazole thioether were significantly higher in poor metabolizers than in extensive metabolizers on day 1 (5357 +/- 883 vs 1131 +/- 512 ng x hr/ml and 1703 +/- 432 vs 561 +/- 358 ng x hr/ml, respectively; p<0.001) and on day 4 (5601 +/- 669 vs 1619 +/- 778 ng x hr/ml and 1914 +/- 378 vs 511 +/- 360 ng x hr/ml, respectively; p<0.001).",Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12820812/),[h·ng] / [ml],1131,37005,DB01129,Rabeprazole
,12820812,area under the concentration-time curve,"The mean +/- SD values of area under the concentration-time curve of rabeprazole and rabeprazole thioether were significantly higher in poor metabolizers than in extensive metabolizers on day 1 (5357 +/- 883 vs 1131 +/- 512 ng x hr/ml and 1703 +/- 432 vs 561 +/- 358 ng x hr/ml, respectively; p<0.001) and on day 4 (5601 +/- 669 vs 1619 +/- 778 ng x hr/ml and 1914 +/- 378 vs 511 +/- 360 ng x hr/ml, respectively; p<0.001).",Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12820812/),[h·ng] / [ml],1703,37006,DB01129,Rabeprazole
,12820812,area under the concentration-time curve,"The mean +/- SD values of area under the concentration-time curve of rabeprazole and rabeprazole thioether were significantly higher in poor metabolizers than in extensive metabolizers on day 1 (5357 +/- 883 vs 1131 +/- 512 ng x hr/ml and 1703 +/- 432 vs 561 +/- 358 ng x hr/ml, respectively; p<0.001) and on day 4 (5601 +/- 669 vs 1619 +/- 778 ng x hr/ml and 1914 +/- 378 vs 511 +/- 360 ng x hr/ml, respectively; p<0.001).",Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12820812/),[h·ng] / [ml],561,37007,DB01129,Rabeprazole
,12820812,area under the concentration-time curve,"The mean +/- SD values of area under the concentration-time curve of rabeprazole and rabeprazole thioether were significantly higher in poor metabolizers than in extensive metabolizers on day 1 (5357 +/- 883 vs 1131 +/- 512 ng x hr/ml and 1703 +/- 432 vs 561 +/- 358 ng x hr/ml, respectively; p<0.001) and on day 4 (5601 +/- 669 vs 1619 +/- 778 ng x hr/ml and 1914 +/- 378 vs 511 +/- 360 ng x hr/ml, respectively; p<0.001).",Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12820812/),[h·ng] / [ml],5601,37008,DB01129,Rabeprazole
,12820812,area under the concentration-time curve,"The mean +/- SD values of area under the concentration-time curve of rabeprazole and rabeprazole thioether were significantly higher in poor metabolizers than in extensive metabolizers on day 1 (5357 +/- 883 vs 1131 +/- 512 ng x hr/ml and 1703 +/- 432 vs 561 +/- 358 ng x hr/ml, respectively; p<0.001) and on day 4 (5601 +/- 669 vs 1619 +/- 778 ng x hr/ml and 1914 +/- 378 vs 511 +/- 360 ng x hr/ml, respectively; p<0.001).",Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12820812/),[h·ng] / [ml],1619,37009,DB01129,Rabeprazole
,12820812,area under the concentration-time curve,"The mean +/- SD values of area under the concentration-time curve of rabeprazole and rabeprazole thioether were significantly higher in poor metabolizers than in extensive metabolizers on day 1 (5357 +/- 883 vs 1131 +/- 512 ng x hr/ml and 1703 +/- 432 vs 561 +/- 358 ng x hr/ml, respectively; p<0.001) and on day 4 (5601 +/- 669 vs 1619 +/- 778 ng x hr/ml and 1914 +/- 378 vs 511 +/- 360 ng x hr/ml, respectively; p<0.001).",Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12820812/),[h·ng] / [ml],1914,37010,DB01129,Rabeprazole
,12820812,area under the concentration-time curve,"The mean +/- SD values of area under the concentration-time curve of rabeprazole and rabeprazole thioether were significantly higher in poor metabolizers than in extensive metabolizers on day 1 (5357 +/- 883 vs 1131 +/- 512 ng x hr/ml and 1703 +/- 432 vs 561 +/- 358 ng x hr/ml, respectively; p<0.001) and on day 4 (5601 +/- 669 vs 1619 +/- 778 ng x hr/ml and 1914 +/- 378 vs 511 +/- 360 ng x hr/ml, respectively; p<0.001).",Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12820812/),[h·ng] / [ml],511,37011,DB01129,Rabeprazole
,28801980,M,"In a retrospective study, patients who received a PPI had significantly higher MTX levels at 48 h (0.38 vs. 0.15 μmol l-1 , respectively, p = 0.000018) and 72 h (0.13 vs. 0.05 μmol l-1 , respectively, p = 0.0002) compared with patients who did not receive a PPI (but received famotidine).",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),[μM] / [l],0.38,37476,DB01129,Rabeprazole
,28801980,M,"In a retrospective study, patients who received a PPI had significantly higher MTX levels at 48 h (0.38 vs. 0.15 μmol l-1 , respectively, p = 0.000018) and 72 h (0.13 vs. 0.05 μmol l-1 , respectively, p = 0.0002) compared with patients who did not receive a PPI (but received famotidine).",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),[μM] / [l],0.15,37477,DB01129,Rabeprazole
,28801980,M,"In a retrospective study, patients who received a PPI had significantly higher MTX levels at 48 h (0.38 vs. 0.15 μmol l-1 , respectively, p = 0.000018) and 72 h (0.13 vs. 0.05 μmol l-1 , respectively, p = 0.0002) compared with patients who did not receive a PPI (but received famotidine).",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),[μM] / [l],0.13,37478,DB01129,Rabeprazole
,28801980,M,"In a retrospective study, patients who received a PPI had significantly higher MTX levels at 48 h (0.38 vs. 0.15 μmol l-1 , respectively, p = 0.000018) and 72 h (0.13 vs. 0.05 μmol l-1 , respectively, p = 0.0002) compared with patients who did not receive a PPI (but received famotidine).",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),[μM] / [l],0.05,37479,DB01129,Rabeprazole
,28801980,IC50,"Moreover, in vitro experiments demonstrated that PPIs (esomeprazole, lansoprazole, omeprazole and rabeprazole) inhibited hOAT3-mediated uptake of MTX in a concentration-dependent manner (IC50 values of 0.40-5.5 μ m), with a rank order of lansoprazole > esomeprazole > rabeprazole > omeprazole.",Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28801980/),m·μ,0.40-5.5,37480,DB01129,Rabeprazole
,12369444,absolute bioavailability,The substance has an absolute bioavailability upon oral administration of approximately 52% which is robust against food intake or administration of antacids.,Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12369444/),%,52,41783,DB01129,Rabeprazole
,12369444,Elimination half-life,Elimination half-life is about 1 h.,Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12369444/),h,1,41784,DB01129,Rabeprazole
,18076214,elimination half-lives,The currently available PPIs have short elimination half-lives ranging from 1 to 1.5 hours.,Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18076214/),h,1 to 1.5,42062,DB01129,Rabeprazole
,31276900,IC50(insulin),Ebselen is the most potent inhibitor (IC50(insulin) = 14 nM).,Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31276900/),nM,14,46523,DB01129,Rabeprazole
,22012670,limit of detection,"The limit of detection is 0.01 ng/ml, and the lower limit of quantitation is 2.0 ng/ml.",Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22012670/),[ng] / [ml],0.01,46739,DB01129,Rabeprazole
,22748970,T(max),"Median T(max) was 2.5 to 3.0 hours, and mean elimination half-life was 1.27 to 1.43 hours.","Randomized, open-label, single-dose, crossover, relative bioavailability study in healthy adults, comparing the pharmacokinetics of rabeprazole granules administered using soft food or infant formula as dosing vehicle versus suspension. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22748970/),h,2.5 to 3.0,47849,DB01129,Rabeprazole
,22748970,elimination half-life,"Median T(max) was 2.5 to 3.0 hours, and mean elimination half-life was 1.27 to 1.43 hours.","Randomized, open-label, single-dose, crossover, relative bioavailability study in healthy adults, comparing the pharmacokinetics of rabeprazole granules administered using soft food or infant formula as dosing vehicle versus suspension. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22748970/),h,1.27 to 1.43,47850,DB01129,Rabeprazole
<,34166834,tmax,GDC-3280 was generally readily absorbed with a median tmax < 4.0 h following single- or repeat-dose oral administration.,"A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34166834/),h,4.0,53344,DB01129,Rabeprazole
,34166834,apparent terminal half-life (t1/2),"Following repeat dose administration, steady-state plasma concentrations of GDC-3280 were achieved within 2 days with an apparent terminal half-life (t1/2) between 5 and 6 h.","A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34166834/),h,5 and 6,53345,DB01129,Rabeprazole
,17377959,CL,"After intravenous administration of RSPI (i.v.: 2, 6 and 18 mg/kg) to rats, no significant dose-dependency was found in the CL (4.20-5.72 l/h/kg), V(area) (d) (0.94-1.32 l/kg), dose-normalized AUC (197.20-245.82 microg/l*h based on 1 mg/kg) and t(1/2) (p>0.05).","Liquid chromatographic-mass spectrometry analysis and pharmacokinetic studies of a novel rabeprazole formulation, sterile powder for injection, in dogs and rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17377959/),[l] / [h·kg],4.20-5.72,54022,DB01129,Rabeprazole
,17377959,V(area) (d),"After intravenous administration of RSPI (i.v.: 2, 6 and 18 mg/kg) to rats, no significant dose-dependency was found in the CL (4.20-5.72 l/h/kg), V(area) (d) (0.94-1.32 l/kg), dose-normalized AUC (197.20-245.82 microg/l*h based on 1 mg/kg) and t(1/2) (p>0.05).","Liquid chromatographic-mass spectrometry analysis and pharmacokinetic studies of a novel rabeprazole formulation, sterile powder for injection, in dogs and rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17377959/),[l] / [kg],0.94-1.32,54023,DB01129,Rabeprazole
,17377959,dose-normalized AUC,"After intravenous administration of RSPI (i.v.: 2, 6 and 18 mg/kg) to rats, no significant dose-dependency was found in the CL (4.20-5.72 l/h/kg), V(area) (d) (0.94-1.32 l/kg), dose-normalized AUC (197.20-245.82 microg/l*h based on 1 mg/kg) and t(1/2) (p>0.05).","Liquid chromatographic-mass spectrometry analysis and pharmacokinetic studies of a novel rabeprazole formulation, sterile powder for injection, in dogs and rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17377959/),[μg] / [h·l],197.20-245.82,54024,DB01129,Rabeprazole
more,15556540,Recovery,Recovery of rabeprazole as well as the internal standard from human plasma was more than 90.0%.,"Direct injection, column switching-liquid chromatographic technique for the estimation of rabeprazole in bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556540/),%,90.0,55361,DB01129,Rabeprazole
,33673019,Tmax,"Further, in vivo beagle pharmacokinetics confirmed that the newly developed IR tablet had an AUCt which is bioequivalent to the existing delayed-release rabeprazole tablet; however, its Tmax was 0.5 h, which is up to seven times faster than that of the existing tablet.",Quality by Design Applied Development of Immediate-Release Rabeprazole Sodium Dry-Coated Tablet. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33673019/),h,0.5,62622,DB01129,Rabeprazole
,16012079,Cmax,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],954,66805,DB01129,Rabeprazole
,16012079,Cmax,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],167,66806,DB01129,Rabeprazole
,16012079,AUC0-24,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],167,66807,DB01129,Rabeprazole
,16012079,AUC0-24,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[nghml],4787,66808,DB01129,Rabeprazole
,16012079,AUC0-24,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[nghml],451,66809,DB01129,Rabeprazole
,16012079,elimination half-life,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),h,2.3,66810,DB01129,Rabeprazole
,16012079,elimination half-life,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),h,1.2,66811,DB01129,Rabeprazole
,16012079,elimination half-life,"In contrast, although the elimination half-life of (R)-rabeprazole was significantly longer than that of the (S)-enantiomer (2.1+/-0.5 vs. 1.3+/-0.9h, respectively; P<0.05), there was no difference in Cmax between the (R)- and (S)-enantiomer (186+/-40 vs. 200+/-92 ngml(-1), respectively).",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),h,2.1,66812,DB01129,Rabeprazole
,16012079,elimination half-life,"In contrast, although the elimination half-life of (R)-rabeprazole was significantly longer than that of the (S)-enantiomer (2.1+/-0.5 vs. 1.3+/-0.9h, respectively; P<0.05), there was no difference in Cmax between the (R)- and (S)-enantiomer (186+/-40 vs. 200+/-92 ngml(-1), respectively).",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),h,1.3,66813,DB01129,Rabeprazole
,16012079,Cmax,"In contrast, although the elimination half-life of (R)-rabeprazole was significantly longer than that of the (S)-enantiomer (2.1+/-0.5 vs. 1.3+/-0.9h, respectively; P<0.05), there was no difference in Cmax between the (R)- and (S)-enantiomer (186+/-40 vs. 200+/-92 ngml(-1), respectively).",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],186,66814,DB01129,Rabeprazole
,16012079,Cmax,"In contrast, although the elimination half-life of (R)-rabeprazole was significantly longer than that of the (S)-enantiomer (2.1+/-0.5 vs. 1.3+/-0.9h, respectively; P<0.05), there was no difference in Cmax between the (R)- and (S)-enantiomer (186+/-40 vs. 200+/-92 ngml(-1), respectively).",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],200,66815,DB01129,Rabeprazole
greater,8925064,recoveries,The recoveries of E3810 enantiomers and internal standard were greater than 91%.,"Enantioselective high-performance liquid chromatographic assay for determination of the enantiomers of a new anti-ulcer agent, E3810, in beagle dog plasma and rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8925064/),%,91,77989,DB01129,Rabeprazole
,27245553,half maximal inhibitory concentration (IC50),"The in vitro inhibition assays on metformin transport were carried out and showed that the half maximal inhibitory concentration (IC50) of rabeprazole on OCT2-mediated metformin transport was 26.0 μM, whereas the IC50 on MATE1-mediated metformin transport inhibition was 4.6 μM.",The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245553/),μM,26.0,78035,DB01129,Rabeprazole
,27245553,IC50,"The in vitro inhibition assays on metformin transport were carried out and showed that the half maximal inhibitory concentration (IC50) of rabeprazole on OCT2-mediated metformin transport was 26.0 μM, whereas the IC50 on MATE1-mediated metformin transport inhibition was 4.6 μM.",The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245553/),μM,4.6,78036,DB01129,Rabeprazole
,27245553,AUC0-12,"The AUC0-12 of metformin plus rabeprazole were 28,276 ± 5187 ng/ml·h, which was significantly higher than AUC0-12 of metformin plus placebo (24,691 ± 3129 ng/ml·h).",The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245553/),[ng] / [h·ml],"28,276",78037,DB01129,Rabeprazole
,27245553,AUC0-12,"The AUC0-12 of metformin plus rabeprazole were 28,276 ± 5187 ng/ml·h, which was significantly higher than AUC0-12 of metformin plus placebo (24,691 ± 3129 ng/ml·h).",The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245553/),[ng] / [h·ml],"24,691",78038,DB01129,Rabeprazole
,17176622,Cmax,"After oral dosing of [14C] rabeprazole, the mean Cmax of total radioactivity was 1,080 +/- 215 ng equivalent/ml with 0.33 +/- 0.13 hours of the mean tmax.",Mass balance study of [14C] rabeprazole following oral administration in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17176622/),[equivalent·ng] / [ml],"1,080",91304,DB01129,Rabeprazole
,17176622,tmax,"After oral dosing of [14C] rabeprazole, the mean Cmax of total radioactivity was 1,080 +/- 215 ng equivalent/ml with 0.33 +/- 0.13 hours of the mean tmax.",Mass balance study of [14C] rabeprazole following oral administration in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17176622/),h,0.33,91305,DB01129,Rabeprazole
,17176622,apparent elimination half-life,The apparent elimination half-life of total [14C] radioactivity was 12.6 +/- 3.4 hours.,Mass balance study of [14C] rabeprazole following oral administration in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17176622/),h,12.6,91306,DB01129,Rabeprazole
,17176622,total [14C] recovery,"The total [14C] recovery in urine and feces was 99.8 +/-0.7% by 168 hours after oral administration of [14C] rabeprazole, and mean cumulative [14C] radioactivity excreted in urine was 90.0 +/- 1.7% by 168 hours and 79.8 +/- 2.5% of the radioactivity was excreted in urine within 24 hours.",Mass balance study of [14C] rabeprazole following oral administration in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17176622/),%,99.8,91307,DB01129,Rabeprazole
,17176622,cumulative [14C] radioactivity excreted,"The total [14C] recovery in urine and feces was 99.8 +/-0.7% by 168 hours after oral administration of [14C] rabeprazole, and mean cumulative [14C] radioactivity excreted in urine was 90.0 +/- 1.7% by 168 hours and 79.8 +/- 2.5% of the radioactivity was excreted in urine within 24 hours.",Mass balance study of [14C] rabeprazole following oral administration in healthy subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17176622/),%,90.0,91308,DB01129,Rabeprazole
greater,16795131,recovery,The recovery of RA was greater than 70%.,Liquid chromatographic/mass spectrometric assay of rabeprazole in dog plasma for a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16795131/),%,70,111312,DB01129,Rabeprazole
,20863007,relative bioavailability,"The 90% confidence interval for the ratio of logarithmically transformed AUC(0-t), AUC(0-infinity) and Cmax were within the bioequivalence limit of 0.80-1.25 and the relative bioavailability of rabeprazole and diclofenac sodium were found to be 98.6% and 98.9% respectively in the test product.",Bioequivalence study of a fixed dose combination tablet containing rabeprazole and diclofenac sodium in healthy Indian subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20863007/),%,98.6,111414,DB01129,Rabeprazole
,20863007,relative bioavailability,"The 90% confidence interval for the ratio of logarithmically transformed AUC(0-t), AUC(0-infinity) and Cmax were within the bioequivalence limit of 0.80-1.25 and the relative bioavailability of rabeprazole and diclofenac sodium were found to be 98.6% and 98.9% respectively in the test product.",Bioequivalence study of a fixed dose combination tablet containing rabeprazole and diclofenac sodium in healthy Indian subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20863007/),%,98.9,111415,DB01129,Rabeprazole
,15704613,absolute bioavailability,The absolute bioavailability of rabeprazole was 51.8%.,Pharmacokinetics of rabeprazole following single intravenous and oral administration to healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15704613/),%,51.8,125091,DB01129,Rabeprazole
,15704613,elimination half-life,"The elimination half-life of rabeprazole sodium (1.47 +/- 0.82 h) after oral administration was significantly longer than the elimination half-life after intravenous administration (1.02 +/- 0.63 h), probably due to slower rate of absorption than that of elimination.",Pharmacokinetics of rabeprazole following single intravenous and oral administration to healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15704613/),h,1.47,125092,DB01129,Rabeprazole
,15704613,elimination half-life,"The elimination half-life of rabeprazole sodium (1.47 +/- 0.82 h) after oral administration was significantly longer than the elimination half-life after intravenous administration (1.02 +/- 0.63 h), probably due to slower rate of absorption than that of elimination.",Pharmacokinetics of rabeprazole following single intravenous and oral administration to healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15704613/),h,1.02,125093,DB01129,Rabeprazole
,15704613,total body clearance,The mean total body clearance was 283 +/- 98 ml/minutes following a 20 mg intravenous dose.,Pharmacokinetics of rabeprazole following single intravenous and oral administration to healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15704613/),[ml] / [min],283,125094,DB01129,Rabeprazole
,25755073,cumulative urinary recovery,"The calculated cumulative urinary recovery just reached 0.04745‰, 1.272‰ and 0.1631‰ of dose within 24h post-dose for rabeprazole, rabeprazole thioether, and desmethyl rabeprazole thioether, respectively, after intravenous infusion administration, indicating that rabeprazole and its two main metabolites undergo substantial non-renal elimination in healthy Chinese volunteers.",Application of a liquid chromatographic/tandem mass spectrometric method to a urinary excretion study of rabeprazole and two of its metabolites in healthy human urine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25755073/),‰,0.04745,125784,DB01129,Rabeprazole
,25755073,cumulative urinary recovery,"The calculated cumulative urinary recovery just reached 0.04745‰, 1.272‰ and 0.1631‰ of dose within 24h post-dose for rabeprazole, rabeprazole thioether, and desmethyl rabeprazole thioether, respectively, after intravenous infusion administration, indicating that rabeprazole and its two main metabolites undergo substantial non-renal elimination in healthy Chinese volunteers.",Application of a liquid chromatographic/tandem mass spectrometric method to a urinary excretion study of rabeprazole and two of its metabolites in healthy human urine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25755073/),‰,1.272,125785,DB01129,Rabeprazole
,25755073,cumulative urinary recovery,"The calculated cumulative urinary recovery just reached 0.04745‰, 1.272‰ and 0.1631‰ of dose within 24h post-dose for rabeprazole, rabeprazole thioether, and desmethyl rabeprazole thioether, respectively, after intravenous infusion administration, indicating that rabeprazole and its two main metabolites undergo substantial non-renal elimination in healthy Chinese volunteers.",Application of a liquid chromatographic/tandem mass spectrometric method to a urinary excretion study of rabeprazole and two of its metabolites in healthy human urine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25755073/),‰,0.1631,125786,DB01129,Rabeprazole
greater,25720462,AUC ratios,"The AUC ratios of omeprazole and erythromycin, which are administered orally to humans, as enteric-coated tablets, were greater than 1.9 in the rats and dogs controlled for gastric acid secretion.",Evaluation of Acid Tolerance of Drugs Using Rats and Dogs Controlled for Gastric Acid Secretion. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25720462/),,1.9,135783,DB01129,Rabeprazole
less,25720462,AUC ratios,"On the contrary, the AUC ratios of clarithromycin, azithromycin, and etoposide (commercially available as a standard immediate-release form) were less than 1.3 each.",Evaluation of Acid Tolerance of Drugs Using Rats and Dogs Controlled for Gastric Acid Secretion. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25720462/),,1.3,135784,DB01129,Rabeprazole
,17377957,area under the plasma concentration-time curves from 0 to 12 h (AUC(0-12)),"The mean daily dose and the dose-adjusted area under the plasma concentration-time curves from 0 to 12 h (AUC(0-12)) of tacrolimus coadministered with rabeprazole or lansoprazole were the lowest and highest, respectively, in CYP2C19 poor metabolizers (PMs) having the CYP3A5*3/*3 genotype (0.084 and 0.112 mg/kg/day and 1.269 and 1.033 ng.h/ml/mg/kg, respectively).","Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17377957/),[h·ng] / [kg·mg·ml],1.269,141953,DB01129,Rabeprazole
,17377957,area under the plasma concentration-time curves from 0 to 12 h (AUC(0-12)),"The mean daily dose and the dose-adjusted area under the plasma concentration-time curves from 0 to 12 h (AUC(0-12)) of tacrolimus coadministered with rabeprazole or lansoprazole were the lowest and highest, respectively, in CYP2C19 poor metabolizers (PMs) having the CYP3A5*3/*3 genotype (0.084 and 0.112 mg/kg/day and 1.269 and 1.033 ng.h/ml/mg/kg, respectively).","Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17377957/),[h·ng] / [kg·mg·ml],1.033,141954,DB01129,Rabeprazole
,7820329,plasma half-life,The mean plasma half-life was about 1.0 hour and was dose-independent.,"Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7820329/),h,1.0,148139,DB01129,Rabeprazole
,7820329,apparent oral clearance,The apparent oral clearance of E3810 ranged from 4.37 to 8.40 ml/min/kg.,"Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7820329/),[ml] / [kg·min],4.37 to 8.40,148140,DB01129,Rabeprazole
,7820329,serum protein binding,The mean serum protein binding was 96.3%.,"Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7820329/),%,96.3,148141,DB01129,Rabeprazole
,20838991,clearances,"The results show that clearance of rabeprazole was affected by CYP2C19 genotypes (average clearances of homEM, hetEM, and PM were 13.9, 11.5, and 8.74 L·h(-1) respectively).",Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20838991/),[l] / [h],13.9,156750,DB01129,Rabeprazole
,20838991,clearances,"The results show that clearance of rabeprazole was affected by CYP2C19 genotypes (average clearances of homEM, hetEM, and PM were 13.9, 11.5, and 8.74 L·h(-1) respectively).",Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20838991/),[l] / [h],11.5,156751,DB01129,Rabeprazole
,20838991,clearances,"The results show that clearance of rabeprazole was affected by CYP2C19 genotypes (average clearances of homEM, hetEM, and PM were 13.9, 11.5, and 8.74 L·h(-1) respectively).",Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20838991/),[l] / [h],8.74,156752,DB01129,Rabeprazole
,15195855,minimum quantifiable concentration,The minimum quantifiable concentration was set at 10 ng/ml [co-efficient of variance (CV) < 10%].,Bioequivalence study of rabeprazole sodium on healthy human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15195855/),[ng] / [ml],10,164232,DB01129,Rabeprazole
,15195855,relative bioavailability,By comparing AUC(o-t) the relative bioavailability of test preparation has been found to be 100.88% of that of reference preparation.,Bioequivalence study of rabeprazole sodium on healthy human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15195855/),%,100.88,164233,DB01129,Rabeprazole
,11768559,half-life,"Actually, all PPIs display chemical activation half-lives at pH 1.0 of a few minutes at the most, while being eliminated from serum with a half-life of about 1 h.",Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11768559/),h,1,175782,DB01129,Rabeprazole
,16715780,E0,"The final PK-PD model incorporated a one-compartment PK model with one-order absorption from the gastroenteric trace, first-order elimination pathway with one fixed-effect genotype modeling, and a full sigmoidal Emax PD model (X +/- SE: E0 = 2.30 +/- 0.189; Emax = 7.32 +/- 0.662; EC50 = 51.3 +/- 2.142 ng/ml; Hill coefficient = 5.00 +/- 0.556).",Pharmacokinetic and pharmacodynamic population modeling of orally administered rabeprazole in healthy Chinese volunteers by the NONMEM method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715780/),,2.30,177872,DB01129,Rabeprazole
,16715780,Emax,"The final PK-PD model incorporated a one-compartment PK model with one-order absorption from the gastroenteric trace, first-order elimination pathway with one fixed-effect genotype modeling, and a full sigmoidal Emax PD model (X +/- SE: E0 = 2.30 +/- 0.189; Emax = 7.32 +/- 0.662; EC50 = 51.3 +/- 2.142 ng/ml; Hill coefficient = 5.00 +/- 0.556).",Pharmacokinetic and pharmacodynamic population modeling of orally administered rabeprazole in healthy Chinese volunteers by the NONMEM method. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715780/),,7.32,177873,DB01129,Rabeprazole
,16715780,EC50,"The final PK-PD model incorporated a one-compartment PK model with one-order absorption from the gastroenteric trace, first-order elimination pathway with one fixed-effect genotype modeling, and a full sigmoidal Emax PD model (X +/- SE: E0 = 2.30 +/- 0.189; Emax = 7.32 +/- 0.662; EC50 = 51.3 +/- 2.142 ng/ml; Hill coefficient = 5.00 +/- 0.556).",Pharmacokinetic and pharmacodynamic population modeling of orally administered rabeprazole in healthy Chinese volunteers by the NONMEM method. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715780/),[ng] / [ml],51.3,177874,DB01129,Rabeprazole
,16715780,Hill coefficient,"The final PK-PD model incorporated a one-compartment PK model with one-order absorption from the gastroenteric trace, first-order elimination pathway with one fixed-effect genotype modeling, and a full sigmoidal Emax PD model (X +/- SE: E0 = 2.30 +/- 0.189; Emax = 7.32 +/- 0.662; EC50 = 51.3 +/- 2.142 ng/ml; Hill coefficient = 5.00 +/- 0.556).",Pharmacokinetic and pharmacodynamic population modeling of orally administered rabeprazole in healthy Chinese volunteers by the NONMEM method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715780/),,5.00,177875,DB01129,Rabeprazole
,29403981,flow rate,The flow rate was set at 0.5 mL/min to elute all the analytes and IS within 1.00 min runtime.,"Development and validation of a high throughput UPLC-MS/MS method for simultaneous quantification of esomeprazole, rabeprazole and levosulpiride in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403981/),[ml] / [min],0.5,188171,DB01129,Rabeprazole
,31844877,absolute bioavailability,The absolute bioavailability of (R)-trelagliptin was identified to be 128.2%.,The Chiral Bioconversion and Pharmacokinetic Analysis of Trelagliptin in Beagle Dog Plasma by LC-MS/MS. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31844877/),%,128.2,188539,DB01129,Rabeprazole
,16783561,AUC(0-infinity),"In the control phase, the AUC(0-infinity) values for rabeprazole and rabeprazole thioether were 1,005+/-366 and 412+/-149 ng.h/ml in homozygous EMs, 1,108+/-340 and 491+/-245 ng.h/ml in heterozygous EMs, and 2,697+/-364 and 2,116+/-373 ng.h/ml in PMs, respectively.",Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16783561/),[h·ng] / [ml],"1,005",192578,DB01129,Rabeprazole
,16783561,AUC(0-infinity),"In the control phase, the AUC(0-infinity) values for rabeprazole and rabeprazole thioether were 1,005+/-366 and 412+/-149 ng.h/ml in homozygous EMs, 1,108+/-340 and 491+/-245 ng.h/ml in heterozygous EMs, and 2,697+/-364 and 2,116+/-373 ng.h/ml in PMs, respectively.",Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16783561/),[h·ng] / [ml],412,192579,DB01129,Rabeprazole
,16783561,AUC(0-infinity),"In the control phase, the AUC(0-infinity) values for rabeprazole and rabeprazole thioether were 1,005+/-366 and 412+/-149 ng.h/ml in homozygous EMs, 1,108+/-340 and 491+/-245 ng.h/ml in heterozygous EMs, and 2,697+/-364 and 2,116+/-373 ng.h/ml in PMs, respectively.",Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16783561/),[h·ng] / [ml],"1,108",192580,DB01129,Rabeprazole
,16783561,AUC(0-infinity),"In the control phase, the AUC(0-infinity) values for rabeprazole and rabeprazole thioether were 1,005+/-366 and 412+/-149 ng.h/ml in homozygous EMs, 1,108+/-340 and 491+/-245 ng.h/ml in heterozygous EMs, and 2,697+/-364 and 2,116+/-373 ng.h/ml in PMs, respectively.",Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16783561/),[h·ng] / [ml],491,192581,DB01129,Rabeprazole
,16783561,AUC(0-infinity),"In the control phase, the AUC(0-infinity) values for rabeprazole and rabeprazole thioether were 1,005+/-366 and 412+/-149 ng.h/ml in homozygous EMs, 1,108+/-340 and 491+/-245 ng.h/ml in heterozygous EMs, and 2,697+/-364 and 2,116+/-373 ng.h/ml in PMs, respectively.",Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16783561/),[h·ng] / [ml],"2,697",192582,DB01129,Rabeprazole
,16783561,AUC(0-infinity),"In the control phase, the AUC(0-infinity) values for rabeprazole and rabeprazole thioether were 1,005+/-366 and 412+/-149 ng.h/ml in homozygous EMs, 1,108+/-340 and 491+/-245 ng.h/ml in heterozygous EMs, and 2,697+/-364 and 2,116+/-373 ng.h/ml in PMs, respectively.",Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16783561/),[h·ng] / [ml],"2,116",192583,DB01129,Rabeprazole
,15871633,time to reach maximum plasma concentration,"Like adults, PPIs are rapidly absorbed in children following oral administration; the mean time to reach maximum plasma concentration varies from 1 to 3 hours.",Pharmacokinetics of proton pump inhibitors in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871633/),h,1 to 3,196990,DB01129,Rabeprazole
,15871633,elimination half-lives,"PPIs are rapidly metabolised in children, with short elimination half-lives of around 1 hour, similar to that reported for adults.",Pharmacokinetics of proton pump inhibitors in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871633/),h,1,196991,DB01129,Rabeprazole
,23512128,half-life,"After irreversible chemical inhibition of the proton pump, such as occurs with pantoprazole, the recovery of the protein of the pump has a half-life of around 50 h.","Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23512128/),h,50,198226,DB01129,Rabeprazole
,15285851,area under the blood concentration-time curve (AUC0-8),"Coadministration of lansoprazole significantly decreased the oral tacrolimus clearance, resulting in an increase in the area under the blood concentration-time curve (AUC0-8) (control vs with lansoprazole: 29.7 +/- 3.5 vs 44.1 +/- 5.0 ng h mL(-1), P < 0.05).",Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15285851/),[h·ng] / [ml],29.7,198748,DB01129,Rabeprazole
,15285851,area under the blood concentration-time curve (AUC0-8),"Coadministration of lansoprazole significantly decreased the oral tacrolimus clearance, resulting in an increase in the area under the blood concentration-time curve (AUC0-8) (control vs with lansoprazole: 29.7 +/- 3.5 vs 44.1 +/- 5.0 ng h mL(-1), P < 0.05).",Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15285851/),[h·ng] / [ml],44.1,198749,DB01129,Rabeprazole
,26249765,Cmax,"In the PK study, after a single intravenous dose of 10, 20, and 40 mg, the main pharmacokinetic parameters for rabeprazole were as follows: Cmax 566.88, 897.23, 2,171.6 ng/mL; AUClast/794.31, 1,122.76, 2,446.85 ng×h/mL, respectively.",Pharmacokinetics and bioavailability in healthy Chinese volunteers of a novel rabeprazole sterile powder formulation for injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26249765/),[ng] / [ml],566.88,202861,DB01129,Rabeprazole
,26249765,Cmax,"In the PK study, after a single intravenous dose of 10, 20, and 40 mg, the main pharmacokinetic parameters for rabeprazole were as follows: Cmax 566.88, 897.23, 2,171.6 ng/mL; AUClast/794.31, 1,122.76, 2,446.85 ng×h/mL, respectively.",Pharmacokinetics and bioavailability in healthy Chinese volunteers of a novel rabeprazole sterile powder formulation for injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26249765/),[ng] / [ml],897.23,202862,DB01129,Rabeprazole
,26249765,Cmax,"In the PK study, after a single intravenous dose of 10, 20, and 40 mg, the main pharmacokinetic parameters for rabeprazole were as follows: Cmax 566.88, 897.23, 2,171.6 ng/mL; AUClast/794.31, 1,122.76, 2,446.85 ng×h/mL, respectively.",Pharmacokinetics and bioavailability in healthy Chinese volunteers of a novel rabeprazole sterile powder formulation for injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26249765/),[ng] / [ml],"2,171.6",202863,DB01129,Rabeprazole
,26249765,AUClast/,"In the PK study, after a single intravenous dose of 10, 20, and 40 mg, the main pharmacokinetic parameters for rabeprazole were as follows: Cmax 566.88, 897.23, 2,171.6 ng/mL; AUClast/794.31, 1,122.76, 2,446.85 ng×h/mL, respectively.",Pharmacokinetics and bioavailability in healthy Chinese volunteers of a novel rabeprazole sterile powder formulation for injection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26249765/),[h·ng] / [ml],794.31,202864,DB01129,Rabeprazole
,26249765,AUClast/,"In the PK study, after a single intravenous dose of 10, 20, and 40 mg, the main pharmacokinetic parameters for rabeprazole were as follows: Cmax 566.88, 897.23, 2,171.6 ng/mL; AUClast/794.31, 1,122.76, 2,446.85 ng×h/mL, respectively.",Pharmacokinetics and bioavailability in healthy Chinese volunteers of a novel rabeprazole sterile powder formulation for injection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26249765/),[h·ng] / [ml],"1,122.76",202865,DB01129,Rabeprazole
,26249765,AUClast/,"In the PK study, after a single intravenous dose of 10, 20, and 40 mg, the main pharmacokinetic parameters for rabeprazole were as follows: Cmax 566.88, 897.23, 2,171.6 ng/mL; AUClast/794.31, 1,122.76, 2,446.85 ng×h/mL, respectively.",Pharmacokinetics and bioavailability in healthy Chinese volunteers of a novel rabeprazole sterile powder formulation for injection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26249765/),[h·ng] / [ml],"2,446.85",202866,DB01129,Rabeprazole
,26249765,Cmax,"After multiple doses of 20 mg, the main pharmacokinetic parameters for rabeprazole were Cmax 991.90 ng/mL, AUClast 1,261.08 ng×h/mL.",Pharmacokinetics and bioavailability in healthy Chinese volunteers of a novel rabeprazole sterile powder formulation for injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26249765/),[ng] / [ml],991.90,202867,DB01129,Rabeprazole
,26249765,AUClast,"After multiple doses of 20 mg, the main pharmacokinetic parameters for rabeprazole were Cmax 991.90 ng/mL, AUClast 1,261.08 ng×h/mL.",Pharmacokinetics and bioavailability in healthy Chinese volunteers of a novel rabeprazole sterile powder formulation for injection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26249765/),[h·ng] / [ml],"1,261.08",202868,DB01129,Rabeprazole
,26249765,Cmax,"In the BA study, after a single oral dose of Pariet® 20 mg, the main pharmacokinetic parameters for rabeprazole were Cmax 582.74 ng/mL, AUClast 1,135.5 ng×h/mL.",Pharmacokinetics and bioavailability in healthy Chinese volunteers of a novel rabeprazole sterile powder formulation for injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26249765/),[ng] / [ml],582.74,202869,DB01129,Rabeprazole
,26249765,AUClast,"In the BA study, after a single oral dose of Pariet® 20 mg, the main pharmacokinetic parameters for rabeprazole were Cmax 582.74 ng/mL, AUClast 1,135.5 ng×h/mL.",Pharmacokinetics and bioavailability in healthy Chinese volunteers of a novel rabeprazole sterile powder formulation for injection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26249765/),[h·ng] / [ml],1,202870,DB01129,Rabeprazole
,26249765,AUClast,"In the BA study, after a single oral dose of Pariet® 20 mg, the main pharmacokinetic parameters for rabeprazole were Cmax 582.74 ng/mL, AUClast 1,135.5 ng×h/mL.",Pharmacokinetics and bioavailability in healthy Chinese volunteers of a novel rabeprazole sterile powder formulation for injection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26249765/),[h·ng] / [ml],135.5,202871,DB01129,Rabeprazole
,26249765,accumulation ratio,"The accumulation ratio was 1.0, suggesting RSPI displayed no accumulation after repeated administration.",Pharmacokinetics and bioavailability in healthy Chinese volunteers of a novel rabeprazole sterile powder formulation for injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26249765/),,1.0,202872,DB01129,Rabeprazole
,21366650,area under the plasma concentration-time curve (AUC(0-12)),"There were no significant differences in the dose-adjusted area under the plasma concentration-time curve (AUC(0-12)) and maximum plasma concentration (C(max)) of tacrolimus between CYP2C19 genotype groups, but there were significant differences between CYP3A5 genotypes groups (*1/*1 + *1/*3 vs. *3/*3 = 45·2 ± 20·0 vs. 71·0 ± 34·1 ng·h/mL/mg, P < 0·0001 and 6·3 ± 2·6 vs. 9·3 ± 7·0 ng/mL/mg, P = 0·0017, respectively) and between co-administration with and without lansoprazole (74·5 ± 34·0 vs. 52·4 ± 27·4 ng·h/mL/mg, P = 0·0054 and 10·9 ± 8·8 vs. 6·7 ± 3·0 ng/mL/mg, P = 0·0024, respectively).",Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366650/),[h·ng] / [mg·ml],45·2,204110,DB01129,Rabeprazole
,21366650,area under the plasma concentration-time curve (AUC(0-12)),"There were no significant differences in the dose-adjusted area under the plasma concentration-time curve (AUC(0-12)) and maximum plasma concentration (C(max)) of tacrolimus between CYP2C19 genotype groups, but there were significant differences between CYP3A5 genotypes groups (*1/*1 + *1/*3 vs. *3/*3 = 45·2 ± 20·0 vs. 71·0 ± 34·1 ng·h/mL/mg, P < 0·0001 and 6·3 ± 2·6 vs. 9·3 ± 7·0 ng/mL/mg, P = 0·0017, respectively) and between co-administration with and without lansoprazole (74·5 ± 34·0 vs. 52·4 ± 27·4 ng·h/mL/mg, P = 0·0054 and 10·9 ± 8·8 vs. 6·7 ± 3·0 ng/mL/mg, P = 0·0024, respectively).",Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366650/),[h·ng] / [mg·ml],71·0,204111,DB01129,Rabeprazole
,21366650,area under the plasma concentration-time curve (AUC(0-12)),"There were no significant differences in the dose-adjusted area under the plasma concentration-time curve (AUC(0-12)) and maximum plasma concentration (C(max)) of tacrolimus between CYP2C19 genotype groups, but there were significant differences between CYP3A5 genotypes groups (*1/*1 + *1/*3 vs. *3/*3 = 45·2 ± 20·0 vs. 71·0 ± 34·1 ng·h/mL/mg, P < 0·0001 and 6·3 ± 2·6 vs. 9·3 ± 7·0 ng/mL/mg, P = 0·0017, respectively) and between co-administration with and without lansoprazole (74·5 ± 34·0 vs. 52·4 ± 27·4 ng·h/mL/mg, P = 0·0054 and 10·9 ± 8·8 vs. 6·7 ± 3·0 ng/mL/mg, P = 0·0024, respectively).",Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366650/),[h·ng] / [mg·ml],74·5,204112,DB01129,Rabeprazole
,21366650,maximum plasma concentration (C(max)),"There were no significant differences in the dose-adjusted area under the plasma concentration-time curve (AUC(0-12)) and maximum plasma concentration (C(max)) of tacrolimus between CYP2C19 genotype groups, but there were significant differences between CYP3A5 genotypes groups (*1/*1 + *1/*3 vs. *3/*3 = 45·2 ± 20·0 vs. 71·0 ± 34·1 ng·h/mL/mg, P < 0·0001 and 6·3 ± 2·6 vs. 9·3 ± 7·0 ng/mL/mg, P = 0·0017, respectively) and between co-administration with and without lansoprazole (74·5 ± 34·0 vs. 52·4 ± 27·4 ng·h/mL/mg, P = 0·0054 and 10·9 ± 8·8 vs. 6·7 ± 3·0 ng/mL/mg, P = 0·0024, respectively).",Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366650/),[ng] / [mg·ml],9·3,204113,DB01129,Rabeprazole
,21366650,maximum plasma concentration (C(max)),"There were no significant differences in the dose-adjusted area under the plasma concentration-time curve (AUC(0-12)) and maximum plasma concentration (C(max)) of tacrolimus between CYP2C19 genotype groups, but there were significant differences between CYP3A5 genotypes groups (*1/*1 + *1/*3 vs. *3/*3 = 45·2 ± 20·0 vs. 71·0 ± 34·1 ng·h/mL/mg, P < 0·0001 and 6·3 ± 2·6 vs. 9·3 ± 7·0 ng/mL/mg, P = 0·0017, respectively) and between co-administration with and without lansoprazole (74·5 ± 34·0 vs. 52·4 ± 27·4 ng·h/mL/mg, P = 0·0054 and 10·9 ± 8·8 vs. 6·7 ± 3·0 ng/mL/mg, P = 0·0024, respectively).",Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366650/),[h·ng] / [mg·ml],74·5,204114,DB01129,Rabeprazole
,21366650,maximum plasma concentration (C(max)),"There were no significant differences in the dose-adjusted area under the plasma concentration-time curve (AUC(0-12)) and maximum plasma concentration (C(max)) of tacrolimus between CYP2C19 genotype groups, but there were significant differences between CYP3A5 genotypes groups (*1/*1 + *1/*3 vs. *3/*3 = 45·2 ± 20·0 vs. 71·0 ± 34·1 ng·h/mL/mg, P < 0·0001 and 6·3 ± 2·6 vs. 9·3 ± 7·0 ng/mL/mg, P = 0·0017, respectively) and between co-administration with and without lansoprazole (74·5 ± 34·0 vs. 52·4 ± 27·4 ng·h/mL/mg, P = 0·0054 and 10·9 ± 8·8 vs. 6·7 ± 3·0 ng/mL/mg, P = 0·0024, respectively).",Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366650/),[h·ng] / [mg·ml],52·4,204115,DB01129,Rabeprazole
,21366650,maximum plasma concentration (C(max)),"There were no significant differences in the dose-adjusted area under the plasma concentration-time curve (AUC(0-12)) and maximum plasma concentration (C(max)) of tacrolimus between CYP2C19 genotype groups, but there were significant differences between CYP3A5 genotypes groups (*1/*1 + *1/*3 vs. *3/*3 = 45·2 ± 20·0 vs. 71·0 ± 34·1 ng·h/mL/mg, P < 0·0001 and 6·3 ± 2·6 vs. 9·3 ± 7·0 ng/mL/mg, P = 0·0017, respectively) and between co-administration with and without lansoprazole (74·5 ± 34·0 vs. 52·4 ± 27·4 ng·h/mL/mg, P = 0·0054 and 10·9 ± 8·8 vs. 6·7 ± 3·0 ng/mL/mg, P = 0·0024, respectively).",Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366650/),[ng] / [mg·ml],10·9,204116,DB01129,Rabeprazole
,21366650,maximum plasma concentration (C(max)),"There were no significant differences in the dose-adjusted area under the plasma concentration-time curve (AUC(0-12)) and maximum plasma concentration (C(max)) of tacrolimus between CYP2C19 genotype groups, but there were significant differences between CYP3A5 genotypes groups (*1/*1 + *1/*3 vs. *3/*3 = 45·2 ± 20·0 vs. 71·0 ± 34·1 ng·h/mL/mg, P < 0·0001 and 6·3 ± 2·6 vs. 9·3 ± 7·0 ng/mL/mg, P = 0·0017, respectively) and between co-administration with and without lansoprazole (74·5 ± 34·0 vs. 52·4 ± 27·4 ng·h/mL/mg, P = 0·0054 and 10·9 ± 8·8 vs. 6·7 ± 3·0 ng/mL/mg, P = 0·0024, respectively).",Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366650/),[ng] / [mg·ml],6·7,204117,DB01129,Rabeprazole
,31667735,AUC0-tz,"In the relative BA study, the gMeans of AUC0-tz (667 to 192 ng h/mL) and Cmax (83.1 to 21.8 ng/mL) were decreased by approximately 70% when the tablet was administered under rabeprazole pretreatment.",Bioequivalence of a Newly Developed Dabigatran Etexilate Tablet Versus the Commercial Capsule and Impact of Rabeprazole-Induced Elevated Gastric pH on Exposure in Healthy Subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31667735/),[h·ng] / [ml],667 to 192,205989,DB01129,Rabeprazole
,31667735,Cmax,"In the relative BA study, the gMeans of AUC0-tz (667 to 192 ng h/mL) and Cmax (83.1 to 21.8 ng/mL) were decreased by approximately 70% when the tablet was administered under rabeprazole pretreatment.",Bioequivalence of a Newly Developed Dabigatran Etexilate Tablet Versus the Commercial Capsule and Impact of Rabeprazole-Induced Elevated Gastric pH on Exposure in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31667735/),[ng] / [ml],83.1 to 21.8,205990,DB01129,Rabeprazole
,16487224,"AUCs(0,infinity)","During placebo administration, the mean AUCs(0,infinity) of rabeprazole in homozygous EMs, heterozygous EMs and PMs were 882 (95% CI, 602, 1162) ng ml-1h , 1214 (975, 1453) ng ml-1 h and 2762 (2482, 3042) ng ml-1 h (P<0.001), respectively.",Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487224/),[ng] / [ml],882,206585,DB01129,Rabeprazole
,16487224,"AUCs(0,infinity)","During placebo administration, the mean AUCs(0,infinity) of rabeprazole in homozygous EMs, heterozygous EMs and PMs were 882 (95% CI, 602, 1162) ng ml-1h , 1214 (975, 1453) ng ml-1 h and 2762 (2482, 3042) ng ml-1 h (P<0.001), respectively.",Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487224/),[h·ng] / [ml],1214,206586,DB01129,Rabeprazole
,16487224,"AUCs(0,infinity)","During placebo administration, the mean AUCs(0,infinity) of rabeprazole in homozygous EMs, heterozygous EMs and PMs were 882 (95% CI, 602, 1162) ng ml-1h , 1214 (975, 1453) ng ml-1 h and 2762 (2482, 3042) ng ml-1 h (P<0.001), respectively.",Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487224/),[h·ng] / [ml],2762,206587,DB01129,Rabeprazole
,10363734,maximum rabeprazole concentration,"The maximum rabeprazole concentration (+/- SD) in subjects with cirrhosis (635+/-199 ng/mL) was approximately 50% higher than that in the healthy volunteers (401+/-246 ng/mL), and both area under the curve and elimination half-life were increased by approximately 100%.","Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363734/),[ng] / [ml],635,215150,DB01129,Rabeprazole
,10363734,maximum rabeprazole concentration,"The maximum rabeprazole concentration (+/- SD) in subjects with cirrhosis (635+/-199 ng/mL) was approximately 50% higher than that in the healthy volunteers (401+/-246 ng/mL), and both area under the curve and elimination half-life were increased by approximately 100%.","Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363734/),[ng] / [ml],401,215151,DB01129,Rabeprazole
,34288547,relative bioavailability,"In addition, the relative bioavailability of lorlatinib oral solution compared with lorlatinib tablets was complete (approximately 108%).",Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34288547/),%,108,219536,DB01129,Rabeprazole
,16402242,t(1/2 ke),"In the homEMs, hetEMs and PMs, the relative AUC(0-infinity) values were 1:2.8:7.5 for omeprazole, 1:1.7:4.0 for lansoprazole and 1:1.6:3.7 for rabeprazole, respectively; the relative t(1/2 ke) values were 1:1.02:1.65 for omeprazole, 1:1.08:2.39 for lansoprazole and 1:1.37:1.85 for rabeprazole, respectively; the relative c(max) values were 1:2.09:4.39 for omeprazole, 1:1.34:1.72 for lansoprazole, and 1:1.24:2.04 for rabeprazole, respectively.",Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16402242/),,1,224766,DB01129,Rabeprazole
,16402242,t(1/2 ke),"In the homEMs, hetEMs and PMs, the relative AUC(0-infinity) values were 1:2.8:7.5 for omeprazole, 1:1.7:4.0 for lansoprazole and 1:1.6:3.7 for rabeprazole, respectively; the relative t(1/2 ke) values were 1:1.02:1.65 for omeprazole, 1:1.08:2.39 for lansoprazole and 1:1.37:1.85 for rabeprazole, respectively; the relative c(max) values were 1:2.09:4.39 for omeprazole, 1:1.34:1.72 for lansoprazole, and 1:1.24:2.04 for rabeprazole, respectively.",Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16402242/),,1.02,224767,DB01129,Rabeprazole
,16402242,t(1/2 ke),"In the homEMs, hetEMs and PMs, the relative AUC(0-infinity) values were 1:2.8:7.5 for omeprazole, 1:1.7:4.0 for lansoprazole and 1:1.6:3.7 for rabeprazole, respectively; the relative t(1/2 ke) values were 1:1.02:1.65 for omeprazole, 1:1.08:2.39 for lansoprazole and 1:1.37:1.85 for rabeprazole, respectively; the relative c(max) values were 1:2.09:4.39 for omeprazole, 1:1.34:1.72 for lansoprazole, and 1:1.24:2.04 for rabeprazole, respectively.",Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16402242/),,1,224768,DB01129,Rabeprazole
,16402242,t(1/2 ke),"In the homEMs, hetEMs and PMs, the relative AUC(0-infinity) values were 1:2.8:7.5 for omeprazole, 1:1.7:4.0 for lansoprazole and 1:1.6:3.7 for rabeprazole, respectively; the relative t(1/2 ke) values were 1:1.02:1.65 for omeprazole, 1:1.08:2.39 for lansoprazole and 1:1.37:1.85 for rabeprazole, respectively; the relative c(max) values were 1:2.09:4.39 for omeprazole, 1:1.34:1.72 for lansoprazole, and 1:1.24:2.04 for rabeprazole, respectively.",Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16402242/),,1,224769,DB01129,Rabeprazole
,16402242,t(1/2 ke),"In the homEMs, hetEMs and PMs, the relative AUC(0-infinity) values were 1:2.8:7.5 for omeprazole, 1:1.7:4.0 for lansoprazole and 1:1.6:3.7 for rabeprazole, respectively; the relative t(1/2 ke) values were 1:1.02:1.65 for omeprazole, 1:1.08:2.39 for lansoprazole and 1:1.37:1.85 for rabeprazole, respectively; the relative c(max) values were 1:2.09:4.39 for omeprazole, 1:1.34:1.72 for lansoprazole, and 1:1.24:2.04 for rabeprazole, respectively.",Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16402242/),,1.08,224770,DB01129,Rabeprazole
,24099279,Tmax,"During the fasting state, GDC-0941 was rapidly absorbed with a median Tmax of 2 h.",Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24099279/),h,2,237927,DB01129,Rabeprazole
,24099279,Tmax,"The presence of a high-fat meal delayed the absorption of GDC-0941, with a median Tmax of 4 h and a modest increase in AUC relative to the fasted state, with an estimated geometric mean ratio (GMR, 90% CI) of fed/fasted of 1.28 (1.08, 1.51) for AUC0-∞ and 0.87 (0.70, 1.06) for Cmax.",Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24099279/),h,4,237928,DB01129,Rabeprazole
,22706585,maximal,The maximal ADP-induced platelet aggregation (2 μmol/L) was decreased in EMs compared with PMs.,Drug-drug interaction of rabeprazole and clopidogrel in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22706585/),[μM] / [l],2,246160,DB01129,Rabeprazole
,9701531,t1/2,The pharmacokinetics of rabeprazole were similar to those of other proton pump inhibitors with a t1/2 of between 0.7 and 1.0 h.,An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9701531/),h,0.7 and 1.0,250659,DB01129,Rabeprazole
,20456825,flow rate,"Following a single step liquid-liquid extraction analytes along with an internal standard (IS) were separated using an isocratic mobile phase of phosphate buffer (10 mM)/acetonitrile (53/47, v/v adjusted pH to 7.3 with triethylamine) at flow rate of 1 mL/min on reverse phase TRACER EXCEL 120 ODS-A column at room temperature.","Improved HPLC method for determination of four PPIs, omeprazole, pantoprazole, lansoprazole and rabeprazole in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20456825/),[ml] / [min],1,253824,DB01129,Rabeprazole
,20456825,Total analytical run time,Total analytical run time for selected PPIs was 10 min.,"Improved HPLC method for determination of four PPIs, omeprazole, pantoprazole, lansoprazole and rabeprazole in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20456825/),min,10,253825,DB01129,Rabeprazole
greater,20456825,recovery of,The recovery of method was equal or greater than 80% and lower limit of quantification (LLOQ) was 20 ng/mL for four PPIs.,"Improved HPLC method for determination of four PPIs, omeprazole, pantoprazole, lansoprazole and rabeprazole in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20456825/),%,80,253826,DB01129,Rabeprazole
,32671657,IC50,"In vitro studies demonstrated that PPIs inhibited rOAT3-mediated uptake of MTX, with estimated IC50 values of 2.1-5.2 μM, and a rank order of esomeprazole ≈ lansoprazole ≈ omeprazole > rabeprazole.",Evaluation of possible pharmacokinetic interaction between methotrexate and proton pump inhibitors in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32671657/),μM,2.1-5.2,258778,DB01129,Rabeprazole
,19360758,flow rate,"The baseline separation of all the peaks was achieved with 0.1% triethylamine (pH 6.0):acetonitrile (72:28, v/v) at a flow rate of 1 mL/min on a Zorbax C(8) column.","Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19360758/),[ml] / [min],1,262031,DB01129,Rabeprazole
,19360758,total chromatographic run time,"The total chromatographic run time was 11.0 min and the simultaneous elution of IS, OPZ, RPZ, PPZ and LPZ occurred at approximately 2.42, 4.45, 5.02 and 9.37 min, respectively.","Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19360758/),min,11.0,262032,DB01129,Rabeprazole
,19360758,total chromatographic run time,"The total chromatographic run time was 11.0 min and the simultaneous elution of IS, OPZ, RPZ, PPZ and LPZ occurred at approximately 2.42, 4.45, 5.02 and 9.37 min, respectively.","Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19360758/),min,2.42,262033,DB01129,Rabeprazole
,19360758,total chromatographic run time,"The total chromatographic run time was 11.0 min and the simultaneous elution of IS, OPZ, RPZ, PPZ and LPZ occurred at approximately 2.42, 4.45, 5.02 and 9.37 min, respectively.","Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19360758/),min,5.02,262034,DB01129,Rabeprazole
,31216902,oral bioavailability,One of the novel prototype formulations showed 70% oral bioavailability relative to the reference product.,Pharmacokinetic evaluation of differential drug release formulations of rabeprazole in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31216902/),%,70,264689,DB01129,Rabeprazole
up,31216902,plasma residence time,"Despite a 30% reduced bioavailability, this showed 1 h delay in peak concentration, longer plasma residence time of rabeprazole (up to 12 h) and longer apparent elimination half-life.",Pharmacokinetic evaluation of differential drug release formulations of rabeprazole in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31216902/),h,12,264690,DB01129,Rabeprazole
,23350044,elimination half-life,PPIs have about 1hour of elimination half-life.,Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23350044/),h,1,271438,DB01129,Rabeprazole
